Table 3.
Follow-up and clinical outcomes post-transplantation
| Transplant waiting time after evaluation (months)a | 5.2±4.6 [3.8; 0.8-19.9] |
|
| |
| Mean interval between pre- and post-transplant CT scans (months)a |
19.3±11.9 [20.8; 2.6-39.3] |
|
| |
| Mean interval between transplant and post- transplant CT scan (months)a |
13.1±8.0 [12.6;0.5-25.2] |
|
| |
| Indication for follow-up CT scan (n, %) | |
| HCC surveillance | 31 (58.5) |
| Rise in transaminases | 6 (11.3) |
| Suspected infection | 7 (13.2) |
| Abdominal pain | 9 (16.9) |
|
| |
| Mean duration of hospital stay (days) | 13.0±9.3 |
|
| |
| Mean duration of ICU stay (days) | 3.2±1.7 |
|
| |
| New onset diabetes (n) | 11 |
|
| |
| Post-transplantation immunosuppression (n, %) | |
| Tacrolimus | 51 (96.2) |
| Mycophenolate mofetil | 41 (77.4) |
| Sirolimus | 8 (15.1) |
| Prednisone | 11 (20.8) |
| Cyclosporine | 3 (5.7) |
|
| |
| Cause of death (n) | |
| Coronary artery disease | 1 |
| Metastatic cancer | 2 |
| Recurrent HCC in graft | 1 |
| Recurrent HCV with renal failure | 1 |
a
Mean±SD [median; range]
CT computed tomography, HCC hepatocellular carcinoma, ICU intensive care unit